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DRUGS IN RELATION TO BLOOD COAGULATION, HAEMOSTASIS
AND THROMBOSIS
PERGAMON PRESS - OXFORD & NEW YORK - 1968
PRINCIPLES OF THE MODE OF ACTION
OF COUMARIN CONGENERS
E. A. LosLrcER and H. C. HBurBn
Haematology Section of the Department of Internal Medicine, University Hospital,
Leiden, and the Thrombosis Service, Leidenu The Netherlands
BrosyNrHnsIs of the four coagulation factors of the so-called prothrom-
bin complex, i.e. factors II, VII, IX, and X, in the hepatic cell depends on
the presence of vitamin K. Vitamin K-antagonists, and among these the
coumarin congeners (comprising 4-hydroxy-coumarin and indan-1 :3-dione
derivatives), induce a reduction in the rate of synthesis of the four coagu-
lation factors as judged from a decrease in their respective activities in the,
blood. The similarity to vitamin K of the chemical structure of the cou-
marin congeners (Fig. 1) suggests that they are likely to compete with
vitamin K. Coagulation factor synthesis is supposed to be blocked at
sites at which an interchange of the physiological vitamin K with the toxic
Frc. 1. Chemical structure of coumarin congeners and vitamin K.
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coumarin congener molecule has occurred' So much for our present
common knowledge.
Although coumarin congeners have now been used' experimentally as
wellastherapeutically,formorelhan2lyears,theirbiochemicalandphar-
macologicalmodeofact ionisst i l lamatterofopinionandthusopento
discussion.
Asanintroductiontothepresentdiscussion'Iwouldliketoputbefore
you some results of our *o'k thut might help to answer some pertinent
questions.
One of the questions we attempted to answer was:
e of factors ll' YII, IX, and X
congeners ?to an initial loading dose of different Goumarln
In an experimental study in man, Van der Esch in our laboratory rrre-
futably demonstrated that different coumarin congeners' administered
in doses sufficiently large to arrest synthesis of factors II' VII' IX' and 
X'
induce identical reactfns:(a) as shown in Fig' 2' 4-8 hours after oral
administrationtheactivitiesofcoagulationfactorsll 'VII'IX'andXstart
to decrease at rates defined by half-times of about 60' 6' 20' and 
40 hours
respectively.(4' 11) These half-iimes found in patients under normal meta-
bolic conditions probably represent the normal metabolic rates of decay
because we were able to p'ouia" evidence that the production rate and 
rate
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Frc. 2. Normal response of factors II, VII, IX' and X to a dose of coumarin 
con-
gener sufficiently large to airest synthesis of the four factors' Ontheordinate
coagulation factor activities are represented in a logarithmic scale'
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Frc . 3. Response of the four factors under pathological conditions : shortened lag
phase and increased isappearance rates in fever, and prolonged lag phase and
decreased isappearance rates in myxoedema.
of metabolic decay of the four factors are independent of the blood level.(12)
It was also found that the rates of decay depend largely upon the metabolic
condition of the person under study. Figure 3 shows that with increased
catabolism, in hyperthyrotic and febrile states, accompanied by a consider-
able reduction of the initial lag phase (down to about 2 hours), a disappear-
anae rate of up to three times the normal may be found; on the other hand,
with decreased catabolism, as in hypothyroidism and possibly also during
late pregnancy and the puerperium, the initial lag phase becomes longer
and the disappearance rate of the coagulation factors appears to be much
slower, down to half normal.(lo)
Practical experience showed that the size of the initial dose of coumarin
congeners must be limited in order to prevent excessive response. However,
the faster the drug is metabolized and excreted, the higher the initial dose
may be. Hence, the initial dose of so-called short-acting coumarin congeners
is often followed by maximum prothrombin response, and the response
to the therapeutically recommended initial dose of a so-called long-acting
coumarin congener is, on the average, slower (Fig. a).
The second question to be answered was:
Is there a common pattern of response of factors II, VII, IX, and X
to the maintenance dose of different coumarin congeners ?
Theoretically, one would expect that after the initial phase of unequable
lowering, the four factors, under the influence of a constant maintenance
dose, i.e. a stable depression ofthe production rate, would reach a constant
and mutually similar degree of lowered activity (Fig. 5). Actually, as
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Fra. 4. schematic representation of the prothrombin response to the initial dose
ofa short-acting and to that ofa long-acting coumarin congener.
shown in Table 1, in patients treated for more than three months under
supervision of our thrombosis service, we did find such a depression;(s' e)
the relatively high factor IX acrivity found in patients treated with Aceno-
coumarol, Warfarin and Dicoumarol, is probably due to the influence of
age and the relatively low factor X activity due to a circulating anticoagu-
lant to be discussed in answer to the next question.
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Frc.5, Schematicrepresentationof theunequable loweringof the activity of the
four factors belonging to the prothrombin complex in response to the initial
loading dose, and of the attainment of an equal depression of all four factors
(down to20%,) during a constant maintenance dose.
MODE OF ACTION OF COUMARIN CONGENERS
T A B L E  1
Drug
Average coag. factor
activity O1)
I I V I I I X X
The third question to be answered was:
Why is the coagulation-factor activity as measured Uy tnromUotest
considerably lower than that obtained from separate coagulation fac-
tor assays ?
It took us quite a long time to find the answer to this question. Since 1960
we had known that 5-10\ thrombotest activity corresponds to a much
higher coagulation-factor activity, but it was only in 1963 that one of us
(H.C.H.) found that the difference appeared to be accounted for by the
appearance in the circulation of an inhibitor, tentatively called prepro-
thrombin.(6) Kinetical studies done invitrodemonstratedthat this circulat-
ing anticoagulant acts as a competitive inhibitor of prothrombin conver-
sion in the sequence of reactions during the coagulation process, most
probably at the site of action of factor X. This characteristic suggests that
the inhibitor is very similar to the substrate of the reaction that is inhif;ited.
It indeed proved to be a protein with adsorption characteristics very similar
to those of the factors of the prothrombin complex. we think this inhibitor
may be a metabolic precursor (of one) of the factors of the prothrombin
complex, but this working hypothesis requires confirmation by the de-
monstration of the synthesis of coagulation factors in vitro. work on this
point is in progress in our laboratory.
An explanatory hypothesis for the appearance of preprothrombin in the
circulation, shown schematically in Fig. 6, may be formulated as follows:
in vitamin K-deflciency the metabolic precursor normally converted into
(one of) the factors of the prothrombin complex in a vitamin K-dependent
step is produced in excess owing to an intracellular feed-back stimulation
of protein synthesis, the stimulus being the lowered intracellular levels
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Frc. 6. Schematic representation of biosynthesis of factors II, VII, IX, and X in
the hepatic cell under influence of vitamin K (Fig. 6a). In case of vitamin K-defi-
ciency (Fig. 6b) the intracellular production of the four factors is lowered (as
indicated by the smaller size of the figures), which feeds back protein synthesis
(indicated by an agglomeration of P's). Preprothrombin is shed in the blood, where
it acts as an inhibitor of the prothrombin complex (indicated by the arrow between
preprothrombin and factor X of the prothrombin complex).
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of factors II, VII, IX, and X. Excess production of this metabolic precursor
tesults in intracellular accumulation and hence delivery into the circulation.
The fact that the amount of inhibitor present in blood is found to be inde-
pendent of the intensity of treatment indicates maximum feed-back sti-
mulation of protein synthesis in vitamin K-deficiency.
The finding of a circulating anticoagulant offers one of the keys to the
solution of the problem of anticoagulant check standards, for it is now
clear that the result of a coagulation check depends on the sensitivity of
the test system not only for prothrombin, factor VII, factor IX, and factor
X, but also for the circulating anticoagulant under discussion. Thrombotest,
which is widely used nowadays as a method of checking anticoagulant
treatment, appears to be particularly sensitive to both the depression of
coagulation factors and the presence of the anticoagulant. As a result
of the action of the inhibitor the coagulation-factor activity in patients
treated with coumarin congeners appears, if measured with thrombotest,
to be only 215 of that expected from the amount of coagulation factors
in the plasma to be tested. The reason why the inhibitor expresses itself
especially in thrombotest is the factthat the final dilution of plasma under
investigation is but 1/10, whereas it is 1/40 or even more in test systems
used for the assessment of the activity of coagulation factors separately.
The fourth and last question to be answered was:
What is the therapeutically optimal range of hypocoagulability ?
We have already known for a number of years thatpowerful prevention
of venous thrombosis undoubtedly requires institution of strong and well-
balanced hypocoagulability.(?' 14' 1?' 18) The "therapeutic range" for pa-
tients who display no contra-indications for anticoagulant treatment is, in
terms of thrombotest, s-rc%.If we look for data concerning the therapeu-
tically optimal range for afteial thrornbosis, there is very little evidence
that in this field, too, the most favourable results can be obtained if a
similar range of hypocoagulability is aimed 41.{1' 5' 15) In a recent double-
blind study(13) we were able to demonstrate that anticoagulant treatment,
continued longer than one year after the occurrence of cardiac infarction,
powerfully prevents reinfarction and other cardiovascular complications
for an unlimited period of time. Phenprocoumon*, which is known to be
superior to other coumarin congeners with respect to stability of hypo-
coagulability,(2' 3' 16) 1ry4s used and tight supervision of patients by the
* We wish to thank the flrm Hoffmann-La Roche for kindly furnishing both the
phenprocoumon (Marcoumar) and the placebo tablets.
20 E. A. LOELIGER AND H. C. HEMKER
?O 15 ru
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THROMBOTEST ACTIVITY (%)
Fro.T.Illustrationofintensityandstabilityoftreatment'basedonrepresentative
samplesofal l116patientsonph"np.ocoumonsti l l inthetr ialaftet!2months
of treatment. The individual average thrombotest values are compiled in classes
of one percent. Solid columns represent values found in the 59 patients without
contraindications,andhatchedcolumnsthosofoundinthe5Tpatientswithcontra.
indications.
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Frc. g. Tentative curve of correlation between results obtained and intensity
of treatment, achieved by different authors in controlled clinical trials. On the
ordinate, the number of (re-)infarctions in patients while on coumarin treatment
is given as percentage of the number found in the control group' On the abscissa"
inlnsity oi treatment is expressed in percentage thrombotest activity (grand
means).
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staff of the thrombosis service could be maintained. Under these circum-
stances, attainment and maintenance of a strong and stable hypocoagula-
bility was found to be feasible without any risk of severe bleeding complica-
tions. The arithmetic mean of all thrombotest values was approximately
8/,. The individual average values varied from 5l to 14f, as shown in
Fig. 7, in which the solid black columns represented the values found in
patients without contra-indications, and hatched columns those found in
patients with relative contra-indications. A comparison of the clinicatr
results of our study with those of other controlled trials made clear that
the more intensively patients are treated, the more they beneflt (Fig. 8).
This may sound like a commonplace to pharmacologists; it is not, however,
part of the common knowledge of investigators dealing with long-term
anticoagulant treatment.
To conclude.' coumarin congeners induce a state of hypocoagulability
that is the result of a depression of the activity of the four coagulation
factors of the prothrombin complex and the appearance in the circulation
of a competitive inhibitor of prothrombin conversion. Depression of the
factors takes place according to well-defined rules, whereas the circulating
anticoagulant remains present in a constant amount. Therapeutic results
depend wholly upon the degree and constancy of hypocoagulability achiev-
ed.Institution of a therapeutic range of 5lto lOflinterms of the com-
mercially available standard thrombotest results in powerful prevention
of venous as well as arterial thrombosis.
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DISCUSSION
B. G. FrmrN, (SYdneY):
could Dr. Loeliger give us some idea of the complication rate, number and age of
patients in his trial ?
E. A. Lonr,rcrn:
The rate of bleeding complications was about 1 in 10 patient-treatment years'
Table 1 illustrates severity of bleeding complications, whereas Table 2 shows their
localization. These complications occurred in 128 patients treated with phenprocoumon'
112 of whichwerestill in trialatthe end of the observation period of 16 months' The
contfol group consisted of 122 patients treated with placebo' Allocation to the trial
took place randomly. The slight difference in number is due to occurrences between the
time of selection of patients and the start of the trial. Only 45-75-year-old male patients,
able to attend the laboratory of the thrombosis service, were included in the study'
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G. RoseNrELp (Sdo Paulo):
Have you seen anytime refractory cases with Phenylindandione? We have seen that
in experiments in dogs, the drug used by the patients was inactive. Can you explain
what can occur with the drug?
E. A. Lorr-rcBr:
Phenylindandione is not used in our country, so I have no answer to your ques-
tion. Perhaps Dr. Jaques or Prof. Born have an explanation.
Dn. heurs:
It is known that the preparation of tablets is all important for reaction to oral
treatment. If the tablet does not disintegrate in the intestinal tract, then resorption will
not occur. In such instances non-reactivity may be misinterpreted as inactivity of or
resistance to the drug.
T A B L E  1
SevERrrv oF BLEEDING Cowlrcerrous
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No change in dosage
Temporary lowering of
Administration of vitamin K,
Blood transfusion
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* Two macrohaematurias, one subarachnoidal bleeding (with complete recovery)-
** Lethal intracerebral bleeding.
T ABLE 2
LocALrzATroN or Br-snorNc
Localization
lrornororou*on
Placebo
Cutaneous
Nasopharyngeal
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Urogenital
Intracranial
Subconjunctival
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J. D. P, Gnluarr,r, (Cardiff):
would Dr. Loeliger care to comment on the mechanism of development of resis-
tance to warfarin in a strain of wild rat in England which is now a serious problem in
pest control.
E. A. Lonr,rcnn:
Development of resistance to warfarin is as far as r can see a pharmacogenetical
problem. But what r wonder about is the fact that the resistance in rats developed
only about 25 years after the introduction of this rat-killer. rn man a certain insen-
sitivity to coumarin congeners is known to be a hereditary trait.*
In my personal experience with almost 20,000 patients treated with coumarin congeners,
I have never observed a case of resistance to the drug. rncidentally we have paiients who
need up to 8 times the mean normal daily dose. we did not perform genetical studies.
* R. A. O'Reilly et al., Hereditary transmission of exceptional resistance to coumarin
anticoagulant drugs. The first reported kindred. New Eng. I. Med.2jl, BOg, (1964).
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